Emerging drugs for ichthyosis.

Abstract

The ichthyoses constitute a large and heterogeneous group of disorders characterised by varying degrees of skin scaling. Most forms are rare but between them, they affect tens of thousands of people worldwide. Treatment presently consists primarily of topical keratolytic agents, aimed at removing the ichthyotic scales, and emollients. If an ichthyosis cannot be controlled by topical therapy alone, retinoids can be used. Although effective in several forms of ichthyosis, side effects and teratogenicity severely limit their use. The recent development of retinoic acid metabolism blocking agents (RAMBAs) offers new possibilities. With these drugs, retinoid effects may be obtained with less side effects and a shorter post-treatment teratogenicity period. This review discusses the RAMBAs that are now in clinical trials and outlines possible future developments.

• Authors: M A M van Steensel
• Journal: Expert opinion on emerging drugs (Expert Opin Emerg Drugs) Vol. 12 Issue 4 Pg. 647-56 (Nov 2007) ISSN: 1744-7623 [Electronic] England
• PMID: 17979605 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Imidazoles
• Keratolytic Agents
• Tretinoin
• liarozole

Topics

• Animals
• Drug Design
• Humans
• Ichthyosis (drug therapy, genetics, immunology, metabolism)
• Imidazoles (adverse effects, chemistry, pharmacology, therapeutic use)
• Keratolytic Agents (adverse effects, chemistry, pharmacology, therapeutic use)
• Molecular Structure
• Tretinoin (adverse effects, metabolism, therapeutic use)